Grace Therapeutics, Inc.
GRCE
$2.14
$0.020.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.23M | 8.67M | 7.63M | 7.16M | 7.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.37M | 11.08M | 11.25M | 12.50M | 14.81M |
| Operating Income | -10.37M | -11.08M | -11.25M | -12.50M | -14.81M |
| Income Before Tax | -21.92M | -9.49M | -7.00M | -9.44M | -12.79M |
| Income Tax Expenses | -1.70M | -1.70M | -1.02M | -1.62M | -2.48M |
| Earnings from Continuing Operations | -20.22 | -7.79 | -5.98 | -7.82 | -10.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.22M | -7.79M | -5.98M | -7.82M | -10.31M |
| EBIT | -10.37M | -11.08M | -11.25M | -12.50M | -14.81M |
| EBITDA | -10.37M | -11.07M | -11.24M | -12.50M | -14.80M |
| EPS Basic | -1.18 | -0.48 | -0.36 | -0.59 | -0.82 |
| Normalized Basic EPS | -0.31 | -0.36 | -0.27 | -0.44 | -0.64 |
| EPS Diluted | -1.18 | -0.48 | -0.36 | -0.59 | -0.82 |
| Normalized Diluted EPS | -0.31 | -0.36 | -0.27 | -0.44 | -0.64 |
| Average Basic Shares Outstanding | 67.38M | 66.04M | 62.61M | 57.19M | 52.77M |
| Average Diluted Shares Outstanding | 67.38M | 66.04M | 62.61M | 57.19M | 52.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |